论文部分内容阅读
本文介绍12例未经治疗的ph~1阳性慢粒细胞性白血病(CML),在确诊后立即联合化疗。结果5例核型转化,其中4例Ph~1阳性细胞降至10%甚至更少。另有2例为嵌合核型,分别降至5%和零。Ph~1阳性CML的嵌合核型,是指核型正常的细胞与Ph~1阳性细胞的结合。据认为,病程中出现这种核型为预后改善,与马利兰治疗有关。某些病例伴一时性骨髓增生不良。这些少数病例中,曾有记载生存期特别长的病例。本组研究的12例,Ph~1阳性细胞除2例分别为50%及95%外,余全为100%。作者采用下列联合化疗:首先给6个疗程化疗,每疗程间歇2～3周。第1天用阿霉素(Doxorubicin)(60mg/m~2)及VCR(1.5mg/m~2);第1～7天用Ara-C(50～100mg/m~2)及6TG(8mg/m~2)。有2例在第1疗程的第7天
This article describes 12 cases of untreated ph-1-positive chronic myeloid leukemia (CML), combined with chemotherapy immediately after diagnosis. Results 5 cases of karyotypic transformation, including 4 cases of Ph ~ 1-positive cells down to 10% or less. Another two cases were chimeric karyotypes, down to 5% and zero respectively. The chimeric karyotype of Ph ~ 1 positive CML refers to the binding of normal karyotype cells to Ph ~ 1 positive cells. It is believed that this karyotype appears during the course of the disease to improve the prognosis, and the treatment of Maryland related. Some cases with transient myelodysplasia. Of these few cases, there were cases of particularly long survival. In this study of 12 cases, Ph ~ 1 positive cells in addition to two cases were 50% and 95%, Yu Quan 100%. The authors used the following combination chemotherapy: first give 6 courses of chemotherapy, each treatment interval of 2 to 3 weeks. Day 1 was treated with Doxorubicin (60 mg / m 2) and VCR (1.5 mg / m 2); Ara-C / m ~ 2). There were 2 cases in the first 7 days of treatment